Neurohormonal & Behavioral Correlates of Obesity and Weight Loss
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Very Low Calorie Diet (VLCD)
Sponsored by

About this trial
This is an interventional basic science trial for Obesity focused on measuring Obesity [C18.654.726.500], Receptor, Opioid, mu [D12.776.543.750.100.620.550], Brain [A08.186.211], Affect [F01.470.047]
Eligibility Criteria
Inclusion Criteria:
- Obese population defined as BMI > 30 kg/m2.
- Lean population BMI < 28 but > 17 kg/m2.
- Able and willing to provide written informed consent for the trial.
- Right handed
- age >/= 18 years
Exclusion Criteria:
- Evidence of inherited disorders of lipid metabolism.
- History of Cancer within the last 5 years except for minor skin cancers
- Human immunodeficiency virus (HIV) antibody positive.
- Patients with solid organ transplants.
- Positive pregnancy screen in Women
- Uncontrolled thyroid disease
- Unstable angina or NY heart association class II failure or above
- Gastrointestinal disease specifically GI motility disorders
- Unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as bulimia or anorexia
- End stage renal or hepatic disease
- Autoimmune disorders (e.g. SLE)
- Body weight fluctuation of more than 5 kg in the previous 3 months
- Prior bariatric surgery
- A history or current alcohol/substance abuse, or opoid abuse/use and change in smoking habits or cessation in the past 6 months.
- Any medical condition, which in the opinion of the investigator would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol.
- Unwilling or unable to consent for the study.
- > 300 lbs (gantry table limit).
- having a waist diameter <53 cm (due to fMRI bore diameter)
Sites / Locations
- University of Michigan Medical School
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
No Intervention
Arm Label
Obese, Weight Loss, Very Low Calorie Diet
Lean, baseline measure
Arm Description
Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
Outcomes
Primary Outcome Measures
Change in [11C]carfentanil binding in brain in response to feeding prior to weight loss
[11C]carfentanil is a µ-opioid receptor selective radiotracer for PET imaging that will be used to asses the function of the µ-opioid receptor (MOR) system in the brains of lean and obese human volunteers. Measurements of [11C]carfentanil binding will be taken following an overnight fast and following the consumption of a standardized meal to determine the change in µ-opioid receptor occupancy (i.e., endogenous opioid release) in response to feeding.
Change in [11C]carfentanil binding in brain in response to feeding post weight loss
[11C]carfentanil is a µ-opioid receptor selective radiotracer for PET imaging that will be used to asses the function of the µ-opioid receptor (MOR) system in the brains of obese human volunteers following diet-induced weight loss. Measurements of [11C]carfentanil binding will be taken following an overnight fast and following the consumption of a standardized meal to determine the change in µ-opioid receptor occupancy (i.e., endogenous opioid release) in response to feeding. Obese individuals will be retested in the fasting and fed state following a 15% weight loss with a Very Low Calorie Diet which is typically achieved within 6 months.
Secondary Outcome Measures
Change in Hunger scores on a visual analog scale in response to feeding at pre weight-loss
Changes in hunger and craving between the fasted (baseline) and fed state will be measured in lean and obese individuals.
Change in Hunger scores on a visual analog scale in response to feeding post weight-loss
Changes in hunger and craving between the fasted (baseline) and fed state will be measured in lean and obese individuals. Obese individuals will be retested in the fasting and fed state following a 15% weight loss with a Very Low Calorie Diet.
Full Information
NCT ID
NCT02063451
First Posted
February 11, 2014
Last Updated
September 20, 2018
Sponsor
University of Michigan
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Brain Research Foundation
1. Study Identification
Unique Protocol Identification Number
NCT02063451
Brief Title
Neurohormonal & Behavioral Correlates of Obesity and Weight Loss
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
February 2011 (Actual)
Primary Completion Date
January 15, 2013 (Actual)
Study Completion Date
January 15, 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Brain Research Foundation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obesity has reached epidemic levels in the United States, and is on the rise in many industrialized nations. The rate of recidivism for long-term weight loss is substantial and presents a critical problem given the importance of obesity as a modifiable risk factor for diseases like type 2 diabetes. Further, the comorbidity of depression with diseases like obesity, type 2 diabetes, and cardiovascular disease suggest that there may be an underlying shared biology for diseases of metabolic dysfunction and emotional dysregulation. The shared biology of these diseases may actually promote the precipitation and exacerbation of comorbid conditions, impacting the success of treatment. Endogenous opioid systems regulate a number of physiological and psychological processes including mood, energy management, and reward. Endogenous opioid µ-receptor-mediated reward processing is thought to be involved both in the short-term control of eating and hedonic food consumption, based on data in animal models. The present proposal will examine the function of the µ-opioid receptor (MOR) system in lean and obese human volunteers following an overnight fast and the change in µ-opioid receptor occupancy (i.e., endogenous opioid release) following the consumption of a standardized meal using PET imaging with the µ-selective radiotracer [11C]carfentanil. The obese individuals will be retested in the fasting and fed state following a 15% weight loss with a Very Low Calorie Diet. Further, the investigators will evaluate the function of the MOR system within the context of the individual's metabolic and psychological profile including aspects of mood and inhibitory control. This information will provide the neurobiological bases to develop novel avenues of intervention based on individual variations in central mechanisms associated with motivational systems and appetite and their potential role in weight regain.
The investigators hypothesize that overeating in chronically obese individuals will be associated with a dysregulation of MOR system function, manifested by reductions in baseline MOR availability (binding potential, BP) in limbic and reward circuitry, and lower release of endogenous opioids after a standard meal, compared to lean volunteers. The latter is observed as acute reductions in the BP measure after meal ingestion.
Detailed Description
Neuroimaging Study. Male and Female volunteers will be recruited from the Investigational Weight Management Clinic (IWMC) at the University of Michigan for this study. All neuropsychological instruments will be collected in lean and obese individuals at baseline, and between 4-6-months. Obese individuals will undergo 4 PET scans: 1) at baseline following an overnight fast; 2) at baseline following consumption of an Ensure shake; 3) after at least a15% reduction in body weight following an overnight fast; 4) and following consumption of an Ensure shake at the post-weight loss time point. Lean individuals will undergo the two scans at baseline after fasting and post-Ensure shake consumption. All lean subjects will consume their normal diets prior to the initial scanning. The obese subjects will undergo their second set of scans, post-weight loss, while still consuming the HMR diet.
Neuroimaging Measures. Two PET studies with [11C]carfentanil (a selective µ-opioid receptor radiotracer) will be acquired for each lean volunteer and 4 PET studies with [11C]carfentanil will be acquired for obese individuals. Structural and functional MRI will be acquired for obese individuals before and after weight loss, and for lean individuals at baseline for co-registration and anatomical standardization of the PET data and activation response to visual stimuli. After their completion, the following data will be used for statistical analyses: 1) Baseline µ-opioid receptor availability in vivo (binding potential, BPND) in lean and obese individuals following an overnight fast. 2) µ-opioid system activation after consuming 500 kcal (16fl oz, 18% protein, 14% CHO, 25% fat) of Ensure shake (fed) in lean and obese individuals as measured by acute reductions in BPND. 3) Baseline MOR BPND in obese individuals who have lost ≥15% of their body weight over 4-6 months (fasting), following an overnight fast. 4) µ-opioid system activation in obese individuals who have lost ≥15% of their body weight after consuming 250 kcal of Ensure shake (fed).
PET Acquisition. Briefly, [11C]carfentanil a selective and specific µ-opioid receptor radioligand, is administered at tracer doses using a bolus/continuous infusion protocol to achieve rapid steady-states between specific and non-specific binding regions (5-7 min post-tracer administration). Twenty-eight frames will be acquired over 70 minutes with an increasing duration (30 sec to 5 min). Two scans will be acquired twice each: A baseline, without challenges, and a scan following consumption of an Ensure shake. Subsequently, dynamic image data for the receptor scans is transformed, on a voxel-by-voxel basis, into parametric maps, and co-registered to each other. These include, 1) a tracer transport measure (K1 ratio, proportional to cerebral blood flow; tracer transport = blood flow x tracer extraction), and receptor-related measures, (BPND), during 2) baseline scans, and 3) following shake consumption. The reduction in BPND from baseline to post-shake consumption represents a measure of endogenous opioid system activation following shake consumption (related to the occupancy and ligand-receptor interactions by the endogenous ligand). These parametric images are calculated using a modified Logan graphical analysis, with the occipital cortex as the reference region. PET images are then co-registered to the T1 MRI structural, anatomical image, affine transformed and warped to standard Montreal Neurological Institute (MNI) stereotactic space using mutual information algorithms. The baseline scan, in the fasted state, will precede the post-consumption scan due to time constraints, and to avoid carry-over effects from active (fed) to baseline (fasted) states. Both PET scans will be performed on the same day to reduce travel time for the subjects and hence experimental burden.
Clinical Measures Psychobehavioral measures to be acquired during the imaging studies include: The Positive and Negative Affect Scale, Profile of Mood Scales, State portion of the Spielberg Anxiety Inventory, and a visual analog scale (VAS) for appetite and palatability will be administered before and after each experiment. These measures will assess emotional state and appetite for correlative purposes with changes in neuroreceptor and circulating hormone levels during performance of the studies. The MINI International Neuropsychiatric Interview (MINI600), Inventory of Depressive Symptomatology (IDS-SR), EuroQol measure of health outcome, Trait portion of the Anxiety Inventory, and NEO Personality Inventory will be obtained prior to scanning for secondary analyses (e.g. relationship between imaging measures and "stable" traits).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity [C18.654.726.500], Receptor, Opioid, mu [D12.776.543.750.100.620.550], Brain [A08.186.211], Affect [F01.470.047]
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Obese, Weight Loss, Very Low Calorie Diet
Arm Type
Other
Arm Description
Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
Arm Title
Lean, baseline measure
Arm Type
No Intervention
Arm Description
MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
Intervention Type
Dietary Supplement
Intervention Name(s)
Very Low Calorie Diet (VLCD)
Intervention Description
Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
Primary Outcome Measure Information:
Title
Change in [11C]carfentanil binding in brain in response to feeding prior to weight loss
Description
[11C]carfentanil is a µ-opioid receptor selective radiotracer for PET imaging that will be used to asses the function of the µ-opioid receptor (MOR) system in the brains of lean and obese human volunteers. Measurements of [11C]carfentanil binding will be taken following an overnight fast and following the consumption of a standardized meal to determine the change in µ-opioid receptor occupancy (i.e., endogenous opioid release) in response to feeding.
Time Frame
baseline and 60 minutes following shake consumption
Title
Change in [11C]carfentanil binding in brain in response to feeding post weight loss
Description
[11C]carfentanil is a µ-opioid receptor selective radiotracer for PET imaging that will be used to asses the function of the µ-opioid receptor (MOR) system in the brains of obese human volunteers following diet-induced weight loss. Measurements of [11C]carfentanil binding will be taken following an overnight fast and following the consumption of a standardized meal to determine the change in µ-opioid receptor occupancy (i.e., endogenous opioid release) in response to feeding. Obese individuals will be retested in the fasting and fed state following a 15% weight loss with a Very Low Calorie Diet which is typically achieved within 6 months.
Time Frame
baseline and 60 minutes post shake consumption
Secondary Outcome Measure Information:
Title
Change in Hunger scores on a visual analog scale in response to feeding at pre weight-loss
Description
Changes in hunger and craving between the fasted (baseline) and fed state will be measured in lean and obese individuals.
Time Frame
baseline and 120 minutes following shake consumption
Title
Change in Hunger scores on a visual analog scale in response to feeding post weight-loss
Description
Changes in hunger and craving between the fasted (baseline) and fed state will be measured in lean and obese individuals. Obese individuals will be retested in the fasting and fed state following a 15% weight loss with a Very Low Calorie Diet.
Time Frame
baseline and 120 minutes following shake consumption
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Obese population defined as BMI > 30 kg/m2.
Lean population BMI < 28 but > 17 kg/m2.
Able and willing to provide written informed consent for the trial.
Right handed
age >/= 18 years
Exclusion Criteria:
Evidence of inherited disorders of lipid metabolism.
History of Cancer within the last 5 years except for minor skin cancers
Human immunodeficiency virus (HIV) antibody positive.
Patients with solid organ transplants.
Positive pregnancy screen in Women
Uncontrolled thyroid disease
Unstable angina or NY heart association class II failure or above
Gastrointestinal disease specifically GI motility disorders
Unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as bulimia or anorexia
End stage renal or hepatic disease
Autoimmune disorders (e.g. SLE)
Body weight fluctuation of more than 5 kg in the previous 3 months
Prior bariatric surgery
A history or current alcohol/substance abuse, or opoid abuse/use and change in smoking habits or cessation in the past 6 months.
Any medical condition, which in the opinion of the investigator would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol.
Unwilling or unable to consent for the study.
> 300 lbs (gantry table limit).
having a waist diameter <53 cm (due to fMRI bore diameter)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul R Burghardt, PhD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan Medical School
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Neurohormonal & Behavioral Correlates of Obesity and Weight Loss
We'll reach out to this number within 24 hrs